Sign In
Buy PFE
$26.04
+0.345 (+1.34%)
At Close: Jun 05, 2026
7 Dividend Stocks to Hold On Tight to for the Next Decade
07:00am, Thursday, 25'th Jul 2024
Here are seven outstanding dividend stocks that stand out for attractive yields and solid fundamentals. They are ideal picks for a long-term investment strategy.
Pfizer (PFE) Gains 7.3% in 2024 on its Weigh-Loss Drug Pipeline
06:51am, Thursday, 25'th Jul 2024
Shares of Pfizer (PFE) are up 7.3% in 2024, based on its weight-loss drug program. The stock must be watched for further developments.
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
06:15am, Thursday, 25'th Jul 2024
Pfizer is busy growing income streams to replace its big COVID-related revenue from years past. Paycom is profitably helping companies help themselves with self-service software.
Beware, Wegovy -- Pfizer Is Working on a Competitor
05:05am, Thursday, 25'th Jul 2024
Pfizer's weight loss candidate is moving closer to pivotal studies. This product had encouraging results in phase 2 studies.
UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant
12:11pm, Wednesday, 24'th Jul 2024
Britain's health regulator said on Wednesday it has authorised Pfizer and BioNTech's updated COVID-19 vaccine that targets the JN.1 subvariant of the coronavirus for use in infants, children and adult
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
12:10pm, Wednesday, 24'th Jul 2024
Sangamo Therapeutics Inc SGMO, which developed a treatment in collaboration with Pfizer Inc PFE, received a boost to its stock price after struggling with liquidity issues.
Pfizer (PFE) Q2 Earnings Coming Up: What Should Investors Do?
10:56am, Wednesday, 24'th Jul 2024
Pfizer ( PFE) will report its second-quarter 2024 earnings on Jul 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.22 billion and 45 cents per share, respec
This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
10:13am, Wednesday, 24'th Jul 2024
Pfizer is developing danuglipron -- a once-daily weight loss drug. In studies of a twice-daily version, some trial participants lost more than 10% of their body weight.
Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
10:04am, Wednesday, 24'th Jul 2024
Pfizer said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. The hemophilia A treatment could be
Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial
07:12am, Wednesday, 24'th Jul 2024
Pfizer said on Wednesday that its gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better t
Earnings Preview: Pfizer (PFE) Q2 Earnings Expected to Decline
11:07am, Tuesday, 23'rd Jul 2024
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
05:59am, Monday, 22'nd Jul 2024
Pfizer and Roche don't have any anti-obesity medicines marketed yet. Both are trying to change that as fast as possible.
Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.
10:00am, Saturday, 20'th Jul 2024
Pfizer doesn't currently produce any anti-obesity medicines, but it wants to do so. However, its most mature program on that front isn't exactly a sizzler.
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
11:40am, Thursday, 18'th Jul 2024
Pfizer Inc PFE, one of the world's largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.
7 Hated Stocks Set to Make a Major Comeback This Year
08:00am, Thursday, 18'th Jul 2024
The stock market has been on a tear lately, but not all stocks are sharing in the gains. A handful of industries and outlier companies are driving the broader market rally, while many other stocks hav
